BridgeBio Pharma (NASDAQ:BBIO) is planning to submit a New Drug Application (NDA) to the FDA in the first half of 2026, with a potential U.S. launch anticipated in late 2026 or early 2027. The company's interim analysis revealed the consistent efficacy of BBP-418 across key clinical endpoints, with early improvements in ambulation observed within three months of treatment. This could make it the first approved therapy for LGMD2I/R9, addressing a significant unmet medical need in this patient population. The firm is also exploring expedited approval pathways in Europe and plans to initiate clinical studies for younger patients with similar conditions. Shares have increased 119.05% over the past 12 months and are currently trading 2.4% above their 20-day simple moving average (SMA) but 3.1% below their 100-day SMA.